Real-time Estimate Cboe BZX 20:22:19 16/07/2024 BST 5-day change 1st Jan Change
12.14 USD -0.12% Intraday chart for Alvotech 0.00% +5.84%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Alvotech Closes $965 Million Loan Facility MT
Alvotech Closes $965 Million Loan Facility MT
Alvotech Announces Closing of Private Debt Financing CI
Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints MT
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva® CI
Alvotech Provides Preliminary Earnings Guidance for the Second Quarter and Six Months Ended June 30, 2024 CI
Alvotech Reports Preliminary Q2 Revenue; Shares Rise Pre-Bell MT
Nordic Stocks Decrease Wednesday; Alvotech Falls Furthest DJ
Alvotech Expects to Issue Up to 22 Million Shares Following Bond Conversion MT
Alvotech, Advanz Pharma Collaborate to Supply, Commercialize Proposed Biosimilar to Eylea in Europe MT
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma MT
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea®? Ld/Hd in Europe CI
Alvotech Appoints Hjörleifur Pálsson as Director CI
Alvotech and STADA Arzneimittel AG Add to Strategic Alliance Through Denosumab Partnership CI
Alvotech Signs Biosimilar Marketing Deal With Stada MT
Alvotech Expands Alliance with STADA to Include Denosumab Biosimilar MT
Alvotech Enters into A New Term Loan Credit Agreement CI
Alvotech Secures Loan Facility of up to $965 Million for Upcoming Launches MT
Alvotech Secures $965 Million Term Loan Facility MT
Alvotech Announces Strategic Refinancing Agreement CI
Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating MT
Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024
Alvotech Raises Revenue Guidance for the Full Year 2024 CI
Alvotech Narrows Q1 Loss as Revenue Increases; Shares Head Higher Premarket MT
Alvotech Narrows Q1 Loss as Revenue Increases MT
Chart Alvotech
More charts
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.1 USD
Average target price
17.5 USD
Spread / Average Target
+44.63%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. News Alvotech
  5. Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma